GlobeNewswire Inc | Sep 28, 2020 07:00AM EDT

September 28, 2020

DURHAM, N.C., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS genome editing platform, today announced its participation in the following upcoming virtual investor conferences:

-- Chardan 4th Annual Genetic Medicines ConferenceDate: Monday, October 5, 2020Time: 8:30 9:00 AM ET -- Jefferies Cell Therapy Summit Date: October 5, 2020Time: 5:30 6:00 PM ET

Live webcasts of each presentation will be accessible on the Companys website www.precisionbiosciences.com, under the Investors & Media section. An archived replay of the webcasts will be available for approximately 30 days following the presentations.

About Precision BioSciences, Inc.Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUSgenome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Companys pipeline consists of multiple off-the-shelf CAR T immunotherapy clinical candidates and severalin vivogene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visitwww.precisionbiosciences.com.

Investor and Media Contact:Maurissa MessierSenior Director, Corporate Communicationsmaurissa.messier@precisionbiosciences.com

Josh RappaportStern Investor Relationsjosh.rappaport@sternir.com